Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis
Objectives Different intrathoracic perfusion therapeutic regimens are available for non-small cell lung cancer with malignant pleural effusion (MPE). Antiangiogenic agents are often used to control MPE, and the results are satisfactory. Here, we performed a network meta-analysis to reveal optimal co...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e080703.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841536617994518528 |
|---|---|
| author | Yan Xu Wei Si Yingying Cui Liming Jiang Yinan Yu Xiaohua Zhu |
| author_facet | Yan Xu Wei Si Yingying Cui Liming Jiang Yinan Yu Xiaohua Zhu |
| author_sort | Yan Xu |
| collection | DOAJ |
| description | Objectives Different intrathoracic perfusion therapeutic regimens are available for non-small cell lung cancer with malignant pleural effusion (MPE). Antiangiogenic agents are often used to control MPE, and the results are satisfactory. Here, we performed a network meta-analysis to reveal optimal combinations of antiangiogenic agents and chemical agents and assess their effectiveness and safety.Design Systematic review and network meta-analysis.Data sources PubMed/Medline, Embase, Cochrane, Web of Science, Wanfang, VIP Database and Chinese National Knowledge Infrastructure were searched from inception to May 2023. Eligible studies were randomised controlled trials that reported on curative effect of MPE.Data extraction and synthesis The Cochrane Collaboration tool was used to assess risk of bias. The consistency was evaluated by examining the agreement between direct and indirect effects. Network meta-analysis was performed and the ranking probabilities of being at each possible rank for each intervention were estimated. Comparison-adjusted funnel plots were obtained to assess publication bias.Results A total of 46 studies were included in the analysis. Among them, we included a total of seven interventions. A total of 3026 patients participated in this analysis. According to the results of the network meta-analysis, some antiangiogenic agents combined with chemotherapy regimens improved objective response rate (ORR) and disease control rate (DCR) and quality of life (QOL). The rank probabilities suggested that in terms of ORR, DCR and QOL, Endostar plus lobaplatin was the first-ranked intervention.Conclusion Administration of antiangiogenic agents plus chemical agents significantly improved the clinical response and QOL. In addition, Endostar plus lobaplatin was the most effective combination.PROSPERO registration number CRD42021284786. |
| format | Article |
| id | doaj-art-a0a2ce7fc1cd4b0e80fc4ab3cfc76970 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-a0a2ce7fc1cd4b0e80fc4ab3cfc769702025-01-14T13:55:12ZengBMJ Publishing GroupBMJ Open2044-60552024-12-01141210.1136/bmjopen-2023-080703Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysisYan Xu0Wei Si1Yingying Cui2Liming Jiang3Yinan Yu4Xiaohua Zhu5Neusoft Medical Systems Co Ltd, Shenyang, China1 Department of Oncology, Shaoxing People`s Hospital, Shaoxing, Zhejiang, China2 Department of Surgery, Yuyao Hospital of Traditional Chinese Medicine, Yuyao, Zhejiang, China1 Department of Oncology, Shaoxing People`s Hospital, Shaoxing, Zhejiang, China1 Department of Oncology, Shaoxing People`s Hospital, Shaoxing, Zhejiang, China1 Department of Oncology, Shaoxing People`s Hospital, Shaoxing, Zhejiang, ChinaObjectives Different intrathoracic perfusion therapeutic regimens are available for non-small cell lung cancer with malignant pleural effusion (MPE). Antiangiogenic agents are often used to control MPE, and the results are satisfactory. Here, we performed a network meta-analysis to reveal optimal combinations of antiangiogenic agents and chemical agents and assess their effectiveness and safety.Design Systematic review and network meta-analysis.Data sources PubMed/Medline, Embase, Cochrane, Web of Science, Wanfang, VIP Database and Chinese National Knowledge Infrastructure were searched from inception to May 2023. Eligible studies were randomised controlled trials that reported on curative effect of MPE.Data extraction and synthesis The Cochrane Collaboration tool was used to assess risk of bias. The consistency was evaluated by examining the agreement between direct and indirect effects. Network meta-analysis was performed and the ranking probabilities of being at each possible rank for each intervention were estimated. Comparison-adjusted funnel plots were obtained to assess publication bias.Results A total of 46 studies were included in the analysis. Among them, we included a total of seven interventions. A total of 3026 patients participated in this analysis. According to the results of the network meta-analysis, some antiangiogenic agents combined with chemotherapy regimens improved objective response rate (ORR) and disease control rate (DCR) and quality of life (QOL). The rank probabilities suggested that in terms of ORR, DCR and QOL, Endostar plus lobaplatin was the first-ranked intervention.Conclusion Administration of antiangiogenic agents plus chemical agents significantly improved the clinical response and QOL. In addition, Endostar plus lobaplatin was the most effective combination.PROSPERO registration number CRD42021284786.https://bmjopen.bmj.com/content/14/12/e080703.full |
| spellingShingle | Yan Xu Wei Si Yingying Cui Liming Jiang Yinan Yu Xiaohua Zhu Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis BMJ Open |
| title | Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis |
| title_full | Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis |
| title_fullStr | Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis |
| title_full_unstemmed | Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis |
| title_short | Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis |
| title_sort | thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non small cell lung cancer a network meta analysis |
| url | https://bmjopen.bmj.com/content/14/12/e080703.full |
| work_keys_str_mv | AT yanxu thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis AT weisi thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis AT yingyingcui thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis AT limingjiang thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis AT yinanyu thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis AT xiaohuazhu thoracicperfusionofantiangiogenicagentscombinedwithchemotherapyfortreatingmalignantpleuraleffusioninnonsmallcelllungcanceranetworkmetaanalysis |